Last Update 03 Apr 26
EVLV: Expanding Stadium And Hospital Contracts Will Drive Long Term Upside
Analysts have modestly adjusted their price target on Evolv Technologies Holdings, keeping fair value at $9.50 while fine tuning assumptions around the discount rate, revenue growth, profit margin, and future P/E to reflect updated views on the company’s risk profile and long term earnings potential.
What's in the News
- Evolv renewed and expanded its subscription agreement with the Houston Astros, upgrading the venue wide deployment at 41,000 seat Daikin Park to Express Gen2 hardware and adding eXpedite bag screening for staff, which brings Evolv’s professional baseball customer count to twelve.
- The company renewed its Evolv Express subscription with the NFL’s Tennessee Titans, updating 17 systems at Nissan Stadium to Gen2 and including both the current and new 60,000 seat domed stadium, with the existing systems planned to be relocated after the 2026 football season.
- Evolv extended and expanded its multi year hardware and software subscription with Bank of America Stadium in Charlotte, upgrading nearly twenty Express units to Gen2 and adding eXpedite bag screening across the 75,000 seat venue.
- Evolv was selected by the American Hospital Association as a Preferred Physical Security Provider, following a multi step vetting process, and reports partnerships with over 500 hospital buildings that screen more than 900,000 visitors and staff each day.
- Evolv Express Gen2 systems and eXpedite scanners were selected for stadium wide use at Inter Miami CF’s new 25,000 seat home at Miami Freedom Park, with Evolv named the Official Fan Screening Provider and gaining ongoing brand presence at the venue.
Valuation Changes
- Fair Value: Held steady at $9.50, with updated inputs not changing the central estimate.
- Discount Rate: Reduced slightly from 8.47% to 8.39%, reflecting a modest adjustment to the assessed risk profile.
- Revenue Growth: Raised slightly from 17.85% to 18.27%, indicating a small upward revision to expected top line expansion in the model.
- Net Profit Margin: Trimmed marginally from 8.19% to 8.08%, suggesting a slightly more conservative view on long term profitability.
- Future P/E: Lowered from 139.15x to 135.79x, implying a modest reset in the multiple applied to future earnings.
Key Takeaways
- Growing regulatory and privacy concerns, alongside commoditization and global competition, threaten Evolv's market adoption and pricing power.
- Reliance on a narrow product suite and ongoing operating losses risk shareholder dilution and declining recurring revenue visibility due to evolving buyer preferences.
- Strong demand drivers, subscription-based growth, ongoing innovation, leadership improvements, and expanding partnerships position the company for sustained top-line and margin growth.
Catalysts
About Evolv Technologies Holdings- Provides artificial intelligence (AI)-based weapons detection for security screening in the United States and internationally.
- Growing public scrutiny over AI-driven surveillance and security, along with the risk of increasingly stringent data privacy regulations like GDPR and CCPA, may sharply hinder adoption of Evolv's solutions in key global markets, leading to slower than projected revenue growth.
- The rapid commoditization and globalization of security screening technologies could intensify price competition, eroding Evolv's premium pricing and compressing gross and net margins over time as average selling prices fall.
- A narrow product suite focused on AI-based weapons detection leaves Evolv vulnerable to technological disruption or being outpaced by larger incumbents and new entrants launching integrated or more advanced multi-system security platforms, threatening long-term revenue sustainability and recurring revenue growth.
- Continued high operating losses, coupled with an ongoing need for significant capital expenditures (as guided between $20 million and $25 million annually) to fund hardware deployment and back-office improvements, increase the likelihood of future shareholder dilution or leveraged balance sheet, suppressing earnings per share.
- Accelerating shifts in buyer preferences toward more unified, end-to-end security ecosystems may marginalize Evolv's standalone solutions, driving lower contract win rates and declining future bookings, thus weakening the expansion of recurring revenue and contracted forward visibility.
Evolv Technologies Holdings Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Evolv Technologies Holdings compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Evolv Technologies Holdings's revenue will grow by 18.3% annually over the next 3 years.
- The bearish analysts are not forecasting that Evolv Technologies Holdings will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Evolv Technologies Holdings's profit margin will increase from -22.7% to the average US Electronic industry of 8.1% in 3 years.
- If Evolv Technologies Holdings's profit margin were to converge on the industry average, you could expect earnings to reach $19.5 million (and earnings per share of $0.09) by about April 2029, up from -$33.1 million today.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 136.2x on those 2029 earnings, up from -32.6x today. This future PE is greater than the current PE for the US Electronic industry at 29.4x.
- The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.39%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The company highlighted strong secular demand drivers such as heightened security concerns, the continued prevalence of gun violence, and new state laws mandating automated weapons detection in hospitals, all of which are likely to sustain or increase demand for Evolv's solutions, potentially boosting long-term revenues and supporting future cash flow growth.
- Evolv's business model is increasingly driven by a subscription and recurring revenue base, as evidenced by an annual recurring revenue of $106 million and retention rates above 90 percent for both units and revenue, which enhances visibility and stability for future revenue streams and could result in improved margin stability.
- Positive early adoption of its new product, Evolv eXpedite, alongside an active Certified Pre-Owned program, demonstrates ongoing innovation and ability to address both new and price-sensitive market segments, providing potential for expanding total addressable market and supporting long-term topline growth.
- The company has successfully resolved significant regulatory and accounting challenges, instituted new leadership with track records in scaling technology businesses, and enacted operational improvements resulting in reduced expenses and first-time positive adjusted EBITDA, which could improve future net margins and enhance investor confidence.
- Expanding partnerships and deployments in diverse verticals, including sports venues, education, and health care, coupled with legislative trends such as new security mandates, may lead to further multi-year contract wins and compounding revenue growth as industry-wide adoption of AI-enabled, frictionless security accelerates.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Evolv Technologies Holdings is $9.5, which represents up to two standard deviations below the consensus price target of $10.0. This valuation is based on what can be assumed as the expectations of Evolv Technologies Holdings's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.5, and the most bearish reporting a price target of just $9.5.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $241.4 million, earnings will come to $19.5 million, and it would be trading on a PE ratio of 136.2x, assuming you use a discount rate of 8.4%.
- Given the current share price of $6.03, the analyst price target of $9.5 is 36.5% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Evolv Technologies Holdings?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.



